```
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 09:31:05 ON 19 NOV 93

 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
 *          W E L C O M E   T O   T H E                        *
 *      U. S.  P A T E N T   T E X T   F I L E                  *
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

=> d his

    (FILE 'USPAT' ENTERED AT 09:31:05 ON 19 NOV 93)
L1          23 S CD4(P)GAMMA
L2           4 S L1(P)(IG OR IMMUNGLOBULIN)
L3          69 S IGG2
L4           8 S L3 AND (CHIMER? OR IMMUNOTOXIN OR SERUM HALF LIFE) AND R
ECO

=> set hi off
'HI OFF' IS NOT A VALID SET OPTION

=> set highlight off
SET COMMAND COMPLETED

=> s (chimer? or immunotoxin or serum half life) and recombinant
         636 CHIMER?
         135 IMMUNOTOXIN
       24730 SERUM
      366792 HALF
      161605 LIFE
          80 SERUM HALF LIFE
              (SERUM(W)HALF(W)LIFE)
        4868 RECOMBINANT
L5        538 (CHIMER? OR IMMUNOTOXIN OR SERUM HALF LIFE) AND RECOMBINANT

=> set highlight on
SET COMMAND COMPLETED

=> s l5 and igg2
          69 IGG2
L6         8 L5 AND IGG2

=> d ti ab pd fd in ccls ab kwic 1-8

US PAT NO:     5,225,538 [IMAGE AVAILABLE]          L6: 1 of 8
TITLE:         Lymphocyte homing receptor/immunoglobulin fusion proteins

ABSTRACT:
Novel polypeptides are provided, together with methods for making and
using them, and nucleic acids encoding them. These polypeptides are
useful as cell surface adhesion molecules and ligands, and are useful in
therapeutic or diagnostic compositions and methods.
DATE ISSUED:   Jul. 6, 1993
DATE FILED:    Dec. 16, 1991
```

INVENTOR: Daniel J. Capon, San Mateo, CA
Laurence A. Lasky, Sausalito, CA
US-CL-CURRENT: 530/387.3; 435/69.7; 530/388.73

ABSTRACT:
Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

CLAIMS:

CLMS(6)

6. The polypeptide of claim 3, wherein the immunoglobulin chain sequence is obtained from IgG1, **IgG2**, IgG3, IgG4, IgA, IgE, IgD or IgM.

US PAT NO: 5,140,105 [IMAGE AVAILABLE] L6: 2 of 8
TITLE: Methods and materials for HIV detection

ABSTRACT:
Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 antibodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passive vaccination procedures.
DATE ISSUED: Aug. 18, 1992
DATE FILED: Feb. 22, 1991
INVENTOR: Tsuneya Ohno, Ridgewood, NJ
US-CL-CURRENT: 530/350; 435/5

ABSTRACT:
Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 antibodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passive vaccination procedures.

DETDESC:

DETD(57)

While . . . are of the IgG.sub.1 isotype, it is expected that antibodies of differing isotypes will be equally useful Antibodies of the

IgG2 isotype, for example, may be more useful in procedures involving complement-mediated cytolytic reactions.

US PAT NO: 5,116,964 [IMAGE AVAILABLE] L6: 3 of 8
TITLE: Hybrid immunoglobulins

ABSTRACT:
Immunoglobulin fusion polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.
DATE ISSUED: May 26, 1992
DATE FILED: Nov. 22, 1989
INVENTOR: Daniel J. Capon, San Mateo, CA
Laurence A. Lasky, Sausalito, CA
US-CL-CURRENT: 536/23.5; 435/69.7, 252.3, 320.1; 530/350; 536/23.51, 23.53

ABSTRACT:
Immunoglobulin fusion polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

CLAIMS:

CLMS(5)

5. The nucleic acid of claim 4 wherein said immunoglobulin chain is obtained from IgG1, **IgG2**, IgG3, IgG4, IgE, IgD or IgM.

US PAT NO: 5,087,557 [IMAGE AVAILABLE] L6: 4 of 8
TITLE: Human monoclonal antibody to lymphadenopathy-associated virus

ABSTRACT:
Human monoclonal antibodies capable of specifically reacting with an antigenic determinant of LAV/HTLV-III and cell lines producing those monoclonal antibodies are disclosed. The human monoclonal antibodies may be utilized in a method for determining the presence of LAV/HTLV-III in biological samples, or in a method for separating specific antigenic determinants of LAV/HTLV-III from a mixture. Pharmaceutical compositions containing such a human monoclonal antibody, and a method for significantly reducing the infectivity of LAV/HTLV-III in animals using the composition are also disclosed.
DATE ISSUED: Feb. 11, 1992
DATE FILED: Mar. 19, 1990
INVENTOR: Janela McClure, Vashon Island, WA
US-CL-CURRENT: 435/5, 7.2, 70.21, 240.27, 974; 436/548, 811; 530/388.15, 388.35

ABSTRACT:
Human monoclonal antibodies capable of specifically reacting with an antigenic determinant of LAV/HTLV-III and cell lines producing those

monoclonal antibodies are disclosed. The human monoclonal antibodies may be utilized in a method for determining the presence of LAV/HTLV-III in biological samples, or in a method for separating specific antigenic determinants of LAV/HTLV-III from a mixture. Pharmaceutical compositions containing such a human monoclonal antibody, and a method for significantly reducing the infectivity of LAV/HTLV-III in animals using the composition are also disclosed.

DETDESC:

DETD(14)

The . . . antigen positive, and secrete monoclonal antibody of either IgG, IgM, IgA, or IgD isotype, including various subtypes such as IgG1, **IgG2**, IgG3 and IgG4. The cell-driven transformation process itself is described in detail in U.S. Pat. No. 4,464,465, which is incorporated. .

US PAT NO: 5,010,176 [IMAGE AVAILABLE] L6: 5 of 8
TITLE: Antibody-drug conjugates

ABSTRACT:
Modified antibodies or antigen-recognizing fragments are prepared with a linker consisting of a malonate, wherein the antibody or fragment thereof is attached through a carbonyl to an ester or amide group on one of the malonate carboxyls, and the drug is linked through a methylene to the 2-position carbon of the malonate.
DATE ISSUED: Apr. 23, 1991
DATE FILED: Nov. 10, 1988
INVENTOR: Russell L. Barton, Indianapolis, IN
US-CL-CURRENT: 530/391.9, 405, 408

ABSTRACT:
Modified antibodies or antigen-recognizing fragments are prepared with a linker consisting of a malonate, wherein the antibody or fragment thereof is attached through a carbonyl to an ester or amide group on one of the malonate carboxyls, and the drug is linked through a methylene to the 2-position carbon of the malonate.

SUMMARY:

BSUM(48)

Plasmid . . . the signal peptide associated with the heavy chain, and a sequence which encodes the heavy chain constant region of human **IgG2**; isolated from E. coli K12 DH5/CH2A5IG2, NRRL B-18361.

US PAT NO: 4,977,247 [IMAGE AVAILABLE] L6: 6 of 8
TITLE: Immobilized protein G variants and the use thereof

ABSTRACT:
Immobilized IgG binding proteins and the use thereof to effect affinity chromatography and separate the subclasses of IgG. Disclosed are

cysteine-containing IgG binding proteins which have high binding capacity for human IgG and mouse monoclonal IgG.
DATE ISSUED: Dec. 11, 1990
DATE FILED: May 19, 1989
INVENTOR: Stephen R. Fahnestock, Olney, MD
Timothy Lee, Gaithersburg, MD
Marie H. Wroble, Mt. Airy, MD
US-CL-CURRENT: 530/350; 435/172.3; 530/387.1, 388.1, 413, 415, 811, 866; 935/11

ABSTRACT:
Immobilized IgG binding proteins and the use thereof to effect affinity chromatography and separate the subclasses of IgG. Disclosed are cysteine-containing IgG binding proteins which have high binding capacity for human IgG and mouse monoclonal IgG.

DETDESC:

DETD(70)

Unexpectedly, the inventors have discovered that the various subclasses of IgG including IgGl, **IgG2**, IgG3, and IgG4 may be fractionated and isolated using the Protein G variant Type 11 immobilized on a solid phase. . .

US PAT NO: 4,975,369 [IMAGE AVAILABLE] L6: 7 of 8
TITLE: Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen

ABSTRACT:
The present invention comprises novel recombinant DNA compounds which encode monoclonal antibody KS1/4 and chimeric derivatives of monoclonal antibody KS1/4. Eukaryotic expression vectors have been constructed that comprise novel KS1/4-encoding DNA and drive expression of KS1/4 when transformed into an appropriate host cell. The novel expression vectors can be used to create modified and chimeric derivatives of KS1/4. The recombinant-produced KS1/4, KS1/4 derivatives and KS1/4 chimeras are useful for the diagnosis, prognosis and treatment of disease states including adenocarcinoma.
DATE ISSUED: Dec. 4, 1990
DATE FILED: Apr. 21, 1988
INVENTOR: Lisa S. Beavers, Trafalgar, IN
Thomas F. Bumol, Carmel, IN
Robert A. Gadski, Indianapolis, IN
Barbara J. Weigel, Indianapolis, IN
US-CL-CURRENT: 435/69.1, 172.3, 240.1, 320.1; 530/387.3, 388.15, 388.85, 867; 536/23.53, 23.72; 935/41, 70, 71

ABSTRACT:
The present invention comprises novel recombinant DNA compounds which encode monoclonal antibody KS1/4 and chimeric derivatives of monoclonal antibody KS1/4. Eukaryotic expression vectors have been constructed that comprise novel KS1/4-encoding DNA and drive expression of KS1/4 when transformed into an appropriate host cell. The novel expression vectors

can be used to create modified and chimeric derivatives of KS1/4. The recombinant-produced KS1/4, KS1/4 derivatives and KS1/4 chimeras are useful for the diagnosis, prognosis and treatment of disease states including adenocarcinoma.

DETDESC:

DETD(43)

Plasmid . . . associated with the heavy chain and a genomic DNA sequence which encodes the heavy chain constant region of human immunoglobulin **IgG2**. Plasmid CH2A5IG2 can be conventionally isolated from E. coli K12 DH5/CH2A5IG2, also deposited and made part of the permanent stock. . .

DETDESC:

DETD(71)

Plasmid pH2-HD, which contains cDNA encoding the heavy chain variable region of KS1/4 joined to genomic DNA encoding a human **IgG2** constant region, was constructed from plasmid phd and plasmid CH2A5IG2. Plasmid CH2A5IG2 was digested with restriction enzyme EcoRI, treated with. . .

DETDESC:

DETD(309)

Plasmid . . . murine monoclonal antibody KS1/4 joined to a genomic DNA fragment which encodes a human heavy chain constant region of immunoglobulin **IgG2**. E. coli K12 DH5/pCH2A5IG2 can be obtained from the Northern Regional Research Laboratories under the accession number NRRL B-18361. A. . .

CLAIMS:

CLMS(44)

44. The recombinant DNA vector of claim 40, wherein the second DNA sequence encodes the constant region of human **IgG2**.

CLAIMS:

CLMS(59)

59. The recombinant DNA expression vector of claim 56 wherein the second DNA sequence encodes the constant region of human **IgG2**.

US PAT NO: 4,808,705 [IMAGE AVAILABLE] L6: 8 of 8
TITLE: Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor

ABSTRACT:

Highly stable pharmaceutical compositions suitable for parenteral administration to animals or humans comprising a therapeutically effective amount of an RTA-immunoconjugate dissolved in an inert carrier method comprising a stabilizer are claimed. Screening methods for selecting stabilizers effective in preventing precipitation and aggregation of such compositions are described. Preferred stabilizers includes glycerol at a concentration (v/v) of from about 25 to about 35%; dextran sulfates having molecular weights from about 0.1.times.10.sup.6 to about 2.times.10.sup.6 daltons; and human serum albumin.
The invention further comprises such compositions which have been lyophilized and/or reconstituted wherein the stabilizer is non-volatile, and may further comprise a carbohydrate stabilizer.
The invention further comprises stabilized RTA compositions.
DATE ISSUED: Feb. 28, 1989
DATE FILED: Dec. 19, 1986
INVENTOR: Robert Ferris, Walnut Creek, CA
US-CL-CURRENT: 424/85.91; 514/2, 8, 885; 530/370, 391.7, 808, 861

ABSTRACT:
Highly stable pharmaceutical compositions suitable for parenteral administration to animals or humans comprising a therapeutically effective amount of an RTA-immunoconjugate dissolved in an inert carrier method comprising a stabilizer are claimed. Screening methods for selecting stabilizers effective in preventing precipitation and aggregation of such compositions are described. Preferred stabilizers includes glycerol at a concentration (v/v) of from about 25 to about 35%; dextran sulfates having molecular weights from about 0.1.times.10.sup.6 to about 2.times.10.sup.6 daltons; and human serum albumin.
The invention further comprises such compositions which have been lyophilized and/or reconstituted wherein the stabilizer is non-volatile, and may further comprise a carbohydrate stabilizer.
The invention further comprises stabilized RTA compositions.

DETDESC:

DETD(9)

The . . . sub-class. Preferably, the monoclonal antibodies of the RTA-immunoconjugates of this invention are in the IgG class, preferably in the IgG1, **IgG2** and IgG3 subclasses, more preferably IgG1 or **IgG2**, and most preferably IgG1.

CLAIMS:
CLMS(18)
18. A composition according to claim 17 wherein said monoclonal antibody is from the IgG1, **IgG2** or IgG3 subclass.
CLAIMS:
CLMS(19)
19. A composition according to claim 18 wherein said subclass is either IgG1 or **IgG2**.

=> logoff y
U.S. Patent & Trademark Office LOGOFF AT 09:39:09 ON 19 NOV 93